{"id":414184,"date":"2021-01-13T09:33:36","date_gmt":"2021-01-13T14:33:36","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=414184"},"modified":"2021-01-13T09:33:36","modified_gmt":"2021-01-13T14:33:36","slug":"therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/","title":{"rendered":"Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Three-Fold Increase in Inflammation Biomarker Observed in Patients with Suicidal Tendencies as Compared to Healthy Controls<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">OCEANSIDE, Calif.<\/span>, <span class=\"xn-chron\">Jan. 13, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today positive preliminary data from the Federally listed clinical trial &#8220;Correlation of Campbell Score with Suicidal Ideation.&#8221;<sup>1 <\/sup><\/p>\n<p>From a group of four healthy controls and four patients with suicidal ideations, the patients with suicidal ideations possessed approximately 3-fold higher levels of the inflammatory cytokine as compared to controls (24.2 \u00b1 7.7 pg\/ml vs 8.4 \u00b12.9 pg\/ml).\u00a0 <\/p>\n<p>The clinical trial is planned to recruit an additional 22 patients and aims to establish validity of the Campbell Score\u2122 as an objective marker to quantify risk of suicide.\u00a0\u00a0\u00a0\u00a0 <\/p>\n<p>&#8220;Currently there are no objective means of knowing the true risk factor for a patient to kill themselves,&#8221; said Dr. <span class=\"xn-person\">James Veltmeyer<\/span>, Chief Medical Officer of Therapeutic Solutions International and Campbell Neurosciences. &#8220;We believe the Campbell Score\u2122 is a first in class diagnostic tool which will not only prevent suicides but will be utilized as a tool for personalizing dosages of various psychiatric medicines and interventions.&#8221;<\/p>\n<p>The Campbell Score\u2122 is currently being developed by Campbell Neurosciences, a partially-owned spinoff of Therapeutic Solutions International.\u00a0 <\/p>\n<p>&#8220;More people die of suicide than in all the wars and natural disasters combined,&#8221; said <span class=\"xn-person\">Kalina O&#8217;Connor<\/span>, President and Chief Executive Officer of Campbell Neurosciences. &#8220;By bringing advanced immunological sciences to the area of psychiatry, we believe we can positively impact the only field of medicine that does not routinely interrogate the organ it is treating.&#8221;<\/p>\n<p>&#8220;Quite exciting to us as a Company is the fact that our nutraceutical product QuadraMune\u2122, which is currently in clinical trials for prevention of COVID-19,<sup>2<\/sup> has been demonstrated to reduce concentrations of the same inflammatory markers assessed in the Campbell Score\u2122,&#8221; said <span class=\"xn-person\">Famela Ramos<\/span>, Vice President of Business Development for Therapeutic Solutions International. &#8220;We are eager to initiate clinical trials utilizing science-based nutraceutical approaches as mono-therapies or adjuvants to existing therapies in order to effectively reduce brain inflammation and inhibit suicidal thoughts.&#8221;<\/p>\n<p>&#8220;The expedience of the Campbell Team in conducting the ongoing trial is unparalleled,&#8221; said <span class=\"xn-person\">Timothy Dixon<\/span>, President and CEO of Therapeutic Solutions International. &#8220;It is an honor to synergize with the work of <span class=\"xn-person\">Miss O&#8217;Connor<\/span> and her team, who are dedicated to finding a cure to suicide using a regenerative psychiatry approach.\u00a0 Therapeutic Solutions International is an &#8220;Innovation Factory&#8221; with programs in cell therapy, immunology and nutraceuticals.\u00a0 Through working with Campbell Neurosciences, we provide broad and deep intellectual property while allowing Campbell Neurosciences to remain laser focused on their mission of &#8220;curing suicide.&#8221;<\/p>\n<p>\n        <b>About Therapeutic Solutions International, Inc.<br \/><\/b>Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company&#8217;s corporate website is <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3036015-1&amp;h=2874961138&amp;u=http%3A%2F%2Fwww.therapeuticsolutionsint.com%2F&amp;a=www.therapeuticsolutionsint.com\" rel=\"nofollow noopener noreferrer\">www.therapeuticsolutionsint.com<\/a>, and our public forum is <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3036015-1&amp;h=2987196145&amp;u=https%3A%2F%2Fboard.therapeuticsolutionsint.com%2F&amp;a=https%3A%2F%2Fboard.therapeuticsolutionsint.com%2F\" rel=\"nofollow noopener noreferrer\">https:\/\/board.therapeuticsolutionsint.com\/<\/a><\/p>\n<p>\n        <b><br \/>\n          <sup>1 <\/sup><br \/>\n        <\/b><br \/>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3036015-1&amp;h=982988398&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04606875&amp;a=Correlation+of+Campbell+Score+With+Suicidal+Ideation+-+Full+Text+View+-+ClinicalTrials.gov\" rel=\"nofollow noopener noreferrer\">Correlation of Campbell Score With Suicidal Ideation &#8211; Full Text View &#8211; ClinicalTrials.gov<\/a><br \/>\n        <b><br \/>\n          <br \/>\n          <sup>2<\/sup>\u00a0<\/b><br \/>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3036015-1&amp;h=4099670271&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04421391&amp;a=QuadraMune(TM)+for+Prevention+of+COVID-19+-+Full+Text+View+-+ClinicalTrials.gov\" rel=\"nofollow noopener noreferrer\">QuadraMune(TM) for Prevention of COVID-19 &#8211; Full Text View &#8211; ClinicalTrials.gov<\/a>\n      <\/p>\n<p>\n        <a target=\"_blank\" href=\"mailto:ir@tsoimail.com\" rel=\"nofollow noopener noreferrer\">ir@tsoimail.com<\/a>\n      <\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=AQ47402&amp;sd=2021-01-13\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences-301207555.html\">http:\/\/www.prnewswire.com\/news-releases\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences-301207555.html<\/a><\/p>\n<p>SOURCE  Therapeutic Solutions International<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=AQ47402&amp;Transmission_Id=202101130930PR_NEWS_USPR_____AQ47402&amp;DateId=20210113\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Three-Fold Increase in Inflammation Biomarker Observed in Patients with Suicidal Tendencies as Compared to Healthy Controls PR Newswire OCEANSIDE, Calif., Jan. 13, 2021 \/PRNewswire\/ &#8212;\u00a0Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today positive preliminary data from the Federally listed clinical trial &#8220;Correlation of Campbell Score with Suicidal Ideation.&#8221;1 From a group of four healthy controls and four patients with suicidal ideations, the patients with suicidal ideations possessed approximately 3-fold higher levels of the inflammatory cytokine as compared to controls (24.2 \u00b1 7.7 pg\/ml vs 8.4 \u00b12.9 pg\/ml).\u00a0 The clinical trial is planned to recruit an additional 22 patients and aims to establish validity of the Campbell Score\u2122 as an objective marker to quantify risk of suicide.\u00a0\u00a0\u00a0\u00a0 &#8220;Currently there are &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-414184","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Three-Fold Increase in Inflammation Biomarker Observed in Patients with Suicidal Tendencies as Compared to Healthy Controls PR Newswire OCEANSIDE, Calif., Jan. 13, 2021 \/PRNewswire\/ &#8212;\u00a0Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today positive preliminary data from the Federally listed clinical trial &#8220;Correlation of Campbell Score with Suicidal Ideation.&#8221;1 From a group of four healthy controls and four patients with suicidal ideations, the patients with suicidal ideations possessed approximately 3-fold higher levels of the inflammatory cytokine as compared to controls (24.2 \u00b1 7.7 pg\/ml vs 8.4 \u00b12.9 pg\/ml).\u00a0 The clinical trial is planned to recruit an additional 22 patients and aims to establish validity of the Campbell Score\u2122 as an objective marker to quantify risk of suicide.\u00a0\u00a0\u00a0\u00a0 &#8220;Currently there are &hellip; Continue reading &quot;Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-13T14:33:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=AQ47402&amp;sd=2021-01-13\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences\",\"datePublished\":\"2021-01-13T14:33:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\\\/\"},\"wordCount\":527,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=AQ47402&amp;sd=2021-01-13\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\\\/\",\"name\":\"Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=AQ47402&amp;sd=2021-01-13\",\"datePublished\":\"2021-01-13T14:33:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=AQ47402&amp;sd=2021-01-13\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=AQ47402&amp;sd=2021-01-13\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/","og_locale":"en_US","og_type":"article","og_title":"Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences - Market Newsdesk","og_description":"Three-Fold Increase in Inflammation Biomarker Observed in Patients with Suicidal Tendencies as Compared to Healthy Controls PR Newswire OCEANSIDE, Calif., Jan. 13, 2021 \/PRNewswire\/ &#8212;\u00a0Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today positive preliminary data from the Federally listed clinical trial &#8220;Correlation of Campbell Score with Suicidal Ideation.&#8221;1 From a group of four healthy controls and four patients with suicidal ideations, the patients with suicidal ideations possessed approximately 3-fold higher levels of the inflammatory cytokine as compared to controls (24.2 \u00b1 7.7 pg\/ml vs 8.4 \u00b12.9 pg\/ml).\u00a0 The clinical trial is planned to recruit an additional 22 patients and aims to establish validity of the Campbell Score\u2122 as an objective marker to quantify risk of suicide.\u00a0\u00a0\u00a0\u00a0 &#8220;Currently there are &hellip; Continue reading \"Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-13T14:33:36+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=AQ47402&amp;sd=2021-01-13","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences","datePublished":"2021-01-13T14:33:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/"},"wordCount":527,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=AQ47402&amp;sd=2021-01-13","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/","name":"Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=AQ47402&amp;sd=2021-01-13","datePublished":"2021-01-13T14:33:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=AQ47402&amp;sd=2021-01-13","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=AQ47402&amp;sd=2021-01-13"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeutic-solutions-international-announces-positive-early-clinical-data-from-ongoing-suicidal-ideation-blood-biomarker-clinical-trial-with-spinoff-campbell-neurosciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/414184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=414184"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/414184\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=414184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=414184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=414184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}